PIG3: A novel link between oxidative stress and DNA damage response in cancer

Cancer Letters

Volumn 327, Issue 1-2, 2012, Pages 97-102

  Kotsinas, Athanassios ^a   Aggarwal, Vimla ^b   Tan, E Jean ^c   Levy, Brynn ^b   Gorgoulis, Vassilis G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b University of Columbia Medical Center ^*  (United States)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

DNA damage response; Oxidative stress; P53; PIG3; Review

Indexed keywords

PROTEIN P53; REACTIVE OXYGEN METABOLITE;

5' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL; CELL CYCLE ARREST; CELL SURVIVAL; CHROMOSOMAL LOCALIZATION; CPG ISLAND; DNA DAMAGE; DNA DAMAGE RESPONSE; GENE; GENE FUNCTION; GENE INACTIVATION; GENE SILENCING; GENE STRUCTURE; GENOTOXICITY; HUMAN; NEOPLASM; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; P53 INDUCIBLE GENE 3; PRIORITY JOURNAL; TRANSCRIPTION REGULATION;

ANIMALS; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; DNA REPAIR; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84867474710     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.12.009     Document Type: Article

References (55)

1. Martindale J.L., Holbrook N.K. Cellular response to oxidative stress: signalling for suicide and survival. J. Cell. Physiol. 2002, 192:1-15.
2. Valko M., Leibfritz D., Moncol J., Cronin M.T.D., Mazur M., Tesler J. Free radicals and antioxidant in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007, 39:44-84.
3. Sedelnikova O.A., Redon C.E., Dickey J.S., Nakamura A.J., Georgakilas A.G., Bonner W.M. Role of oxidatively induced DNA lesions in human pathogenesis. Mutat. Res. 2010, 704:152-159.
4. Kryston T.B., Georgiev A.B., Pissis P., Georgakilas A.G. Role of oxidative stress and DNA damage in human carcinogenesis. Mutat. Res. 2011, 711:193-201.
5. Cadet J., Douki T., Ravanat J.L. Oxidatively generated base damage to cellular DNA. Free Radic. Biol. Med. 2010, 49:9-21.
6. K. Aziz, S. Nowsheen, G. Pantelias, G. Iliakis, V. Gorgoulis, A.G. Georgakilas, Targeting DNA damage and repair: embracing the pharmacological era for successful cancer therapy, Pharmacol. Ther. (2011), in press.
7. Sablina A.A., Budanov A.V., Ilyinskaya G.V., Agapova L.S., Kravchenko J.E., Chumakov P.M. The antioxidant function of the p53 tumor suppressor. Nat. Med. 2005, 11:1306-1313.
8. Polyak K., Xia Y., Zweier J.L., Kinzler K.W., Vogelstein B. A model for p53-induced apoptosis. Nature 1997, 389:300-305.
9. Kimura K., Wakamatsu A., Suzuki Y., et al. Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes. Genome Res. 2006, 16:55-65.
10. Rao P.V., Krishna C.M., Zigler J.S. Identification and characterization of the enzymatic activity of zeta-crystallin from guinea PIG lens. A novel NADPH: quinine oxidoreductase. J. Biol. Chem. 1992, 267:96-102.
11. Porté S., Valencia E., Yakovtseva E.A., Borràs E., Shafqat N., Debreczeny J.É., Pike A.C.W., Oppermann U., Farrés J., Fita I., Parés X. Three-dimensional structure and enzymatic function of proapoptotic human p53-inducible quinine oxidoreductase PIG3. J. Biol. Chem. 2009, 284:17194-17205.
12. El-Deiry W.S., Kern S.E., Pietenpol J.A., Kinzler K.W., Vogelstein B. Definition of a consensus binding site for p53. Nat. Genet. 1992, 1:45-49.
13. Venot C., Maratrat M., Dureuil C., Conseiller E., Bracco L., Debussche L. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J. 1998, 17:4668-4679.
14. Contente A., Dittmer A., Koch M.C., Roth J., Dobbelstein M. A polymorphic microsatellite that mediates induction of PIG3 by p53. Nat. Genet. 2002, 30:315-320.
15. Gorgoulis A.G., Liloglou T., Sigala F., Korkolis D., Yannoukakos D., Papalambros E., Asimacopoulos P.J., Papavassiliou A.G., Kotsinas A. Absence of association with cancer risk and low frequency of alterations at a p53 responsive PIG3 gene polymorphism in breast and lung carcinomas. Mutat. Res. 2004, 556:143-150.
16. Ito M., Nishiyama H., Watanabe J., Kawanishi H., Takahashi T., Kamoto T., Habuchi T., Ogawa O. Association of the PIG3 promoter polymorphism with invasive bladder cancer in a Japanese population. Jpn. J. Clin. Oncol. 2006, 36:116-120.
17. Contente A., Zischler H., Einspanier A., Dobbelstein M. A promoter that acquired p53 responsiveness during primate evolution. Cancer Res. 2003, 63:1756-1758.
18. Kotsinas A., Gorgoulis V.G., Zacharatos P., Mariatos G., Kokotas S., Liloglou T., Ikonomopoulos J., Zoumpourlis V., Kyroudi A., Field J.K., Asimacopoulos P.J., Kittas C. Additional characterization of a hexanucleotide polymorphic site in the first intron of human H-ras gene: comparative study of its alterations in non-small cell lung carcinomas and sporadic invasive breast carcinomas. Cancer Genet. Cytogenet. 2001, 126:147-154.
19. Xie P., Tian C., An L., Nie J., Lu K., Xing G., Zhang L., He F. Histone methyltransferase protein SETD2 interacts with p53 and selectively regulates its downstream genes. Cell. Signal. 2008, 20:1671-1678.
20. MacLachlan T.K., Takimoto R., El-Deiry W.S. BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. Mol. Cell. Biol. 2002, 22:4280-4292.
21. Tanaka T., Ohkubo S., Tatsuno I., Prives C. hCAS/CSE1L associates with chromatin and regulates expression of select p53 target genes. Cell 2007, 130:638-650.
22. 3 receptor. Nucleic Acids Res. 2006, 34:543-554.
23. Liang H., Lunec J. Characterisation of a novel p53 down-regulated promoter in intron 3 of the human MDM2 oncogene. Gene 2005, 361:112-118.
24. Reczek E.E., Flores E.R., Tsay A.S., Attardi L.D., Jacks T. Multiple response elements and differential p53 binding control Perp expression during apoptosis. Mol. Cancer Res. 2003, 1:1048-1057.
25. Nicholls C.D., Shields M.A., Lee P.W., Robbins S.M., Beattie T.L. UV-dependent alternative splicing uncouples p53 activity and PIG3 gene function through rapid proteolytic degradation. J. Biol. Chem. 2004, 279:24171-24178.
26. Kotsinas A., Pateras I.S., Galanos P.S., Karamouzis M.V., Sfikakis P.P., Gorgoulis V.G. Why is p53-inducible gene 3 rarely affected in cancer?. Oncogene 2010, 29:5220.
27. Nicholl C.D., Beattie T.L. Multiple factors influence the normal and UV-inducible alternative splicing of PIG3. Biochim. Biophys. Acta 2008, 1779:838-849.
28. Amano T., Nakamizo A., Mishra S.K., Gumin J., Shinojima N., Sawaya R., Lang F.F. Simultaneous phosphorylation of p53 at serine 15 and 20 induces apoptosis in human glioma cells by increasing expression of pro-apoptotic genes. J. Neurooncol. 2009, 92:357-371.
29. Terui T., Murakami K., Takimoto R., et al. Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors. Cancer Res. 2003, 63:8948-8954.
30. Flatt P.M., Polyak K., Tang L.J., Scatena C.D., Westfall M.D., Rubinstein L.A., Yu J., Kinzler K.W., Vogelstein B., Hill D.E., Pietenpol J. p53-dependent expression of PIG3 during proliferation, genotoxic stress, and reversible growth arrest. Cancer Lett. 2000, 156:63-72.
31. Szak S.T., Mays D., Pietenpol J.A. Kinetics of p53 binding to promoter sites in vivo. Mol. Cell. Biol. 2002, 21:3375-3386.
32. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature 2000, 408:307-310.
33. Halazonetis T., Gorgoulis V.G., Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008, 319:1352-1355.
34. Roth J., Koch P., Contente A., Dobbelstein M. Tumor-derived mutations within the DNA-binding domain of p53 that phenotypically resemble the deletion of the proline-rich domain. Oncogene 2000, 19:1834-1842.
35. Willis A., Jung E.J., Wakefield T., Chen X. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 2004, 23:2330-2338.
36. Pospisilova S., Siligan C., Ban J., Jug G., Kovar H. Constitutive and DNA damage inducible activation of PIG3 and MDM2 genes by tumor-derived p53 mutant C277Y. Mol. Cancer Res. 2004, 2:296-304.
37. Nomdedéu J.F., Perea G., Estivill C., Lasa A., Brunet S., Avent́i{dotless}n A., Sierra J. Loss of heterozygosity of the polymorphic PIG3 microsatellite with low frequency in de novo acute leukemias. Leukemia 2004, 18:1148-1149.
38. Nomdedéu J.F., Perea G., Estivill C., Badell I., Lasa A., Aventín A. Microsatellite instability may involve the pentanucleotide repeat of the PIG3 promoter in bcr/abl acute lymphoblastic leukemia. Leuk. Res. 2008, 32:186-188.
39. Serrano E., Carnicer M.J., Orantes V., Estivill C., Lasa A., Brunet S., Aventín A.M., Sierra J., Nomdedéu J.F. Uniparental disomy may be associated with microsatellite instability in acute myeloid leukemia (AML) with a normal karyotype. Leuk. Lymphoma 2008, 49:1178-1183.
40. Liu C., Wu M.C., Chen F., Ter-Minassian M., Asomaning K., Zhai R., Wang Z., Su L., Heist R.S., Kulke M.H., Lin X., Liu G., Christiani D.C. A Large-scale genetic association study of esophageal adenocarcinoma risk. Carcinogenesis 2010, 31:1259-1263.
41. Liang X., Caporaso N., McMaster M.L., Ng D., Landgren O., Yeager M., Chanock S., Goldin L.R. Common genetic variants in candidate genes and risk of familial lymphoid malignancies. Br. J. Haematol. 2009, 146:418-423.
42. Guey L.T., Garcia-Closas M., Murta-Nascimento C., et al. Genetic susceptibility to distinct bladder cancer subphenotypes. Eur. Urol. 2010, 57:283-292.
43. Hosgood H.D., Zhang L., Shen M., Berndt S.I., Vermeulen R., Li G., Yin S., Yeager M., Yuenger J., Rothman N., Chanock S., Smith M., Lan Q. Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity. Occup. Environ. Med. 2009, 66:848-853.
44. Lee J.-H., Kang Y., Khare V., Jin Z.-Y., Kang M.-Y., Yoon Y., Hyun J.-W., Chung M.-H., Cho S.-I., Jun J.Y., Chang I.-Y., You H.J. The p53-inducible gene 3 (PIG3) contributes to early cellular response to DNA damage. Oncogene 2010, 29:1431-1450.
45. Brown N.S., Bicknell R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res. 2001, 3:323-327.
46. Nishikawa M. Reactive oxygen species in tumor metastasis. Cancer Lett. 2008, 266:53-59.
47. Higashitsuji H., Higashitsuji H., Masuda T., Liu Y., Itoh K., Fujita J. Enhanced deacetylation of p53 by the anti-apoptotic protein HSCO in association with histone deacetylase. J. Biol. Chem. 2007, 282:13716-13725.
48. Tai C.-J., Hsu C.-H., Shen S.-C., Lee W.-R., Jiang M.-C. Cellular apoptosis susceptibility (CSE1L/CAS) protein in cancer metastasis and chemotherapeutic drug induced apoptosis. J. Exp. Clin. Cancer Res. 2010, 29:110-118.
49. Zhang Q., Zhao X.H., Wang Z.J. Flavones and flavonols exert cytotoxic effects on a human oesophageal adenocarcinoma cell line (OE33) by causing G2/M arrest and inducing apoptosis. Food Chem. Toxicol. 2008, 46:2042-2053.
50. Guo Z., Kozlov S., Lavin M.F., Person M.D., Paull T.T. ATM activation by oxidative stress. Science 2010, 330:517-521.
51. Gorgoulis V.G., Vassiliou L.V., Karakaidos P., et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434:907-913.
52. Bartkova J., Horejsí Z., Koed K., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864-870.
53. Bartkova J., Rezaei N., Liontos M., et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006, 444:633-637.
54. Di Micco R., Fumagalli M., Cicalese A., et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006, 444:638-642.
55. Shaheen M., Allen C., Nickoloff J.A., Hromas R. Synthetic lethality: exploiting the addiction of cancer to DNA repair. Blood 2011, 117:6074-6082.